Our data also indicate that EphA2 significantly contributes to OS cell migration/invasion and tumor growth and reduces the sensitivity of OS cells to a commonly used chemotherapeutic drug, cisplatin, potentially through the activation of SRC, AKT and/or ERK–MAPK pathways. Here, EPHA2 is linked to neoplasm.